Key result
3D-QSAR analysis of novel purine derivatives yielded significant correlation coefficients (r2 = 0.821, rcv2 = 0.807), suggesting rational substituent modification can guide antithrombotic drug development.
Why the study?
Purine derivatives possess antiplatelet aggregation activity, making it essential to evaluate the relationship between purine structure and antiplatelet effects to aid antithrombotic drug discovery.
Effect estimate: r2 = 0.821
Rational modification of purine derivative substituent groups can provide a basis for developing novel antithrombotic drugs.
Novel purine modifications merit preclinical testing; leaves open clinical translation for antithrombotic use.
Cardiovascular disease caused by platelet aggregation is a serious threat to human health, so antiplatelet aggregation has great significance to treat the disease. Since, purine derivatives are important molecules with antiplatelet aggregation activity, it is very essential to study the relationship between purine structure and antiplatelet aggregation effect, which could help us to find antithrombotic drugs. This article describes the modification of molecular substituents with purine structures as backbone and evaluates their antiplatelet aggregation activity. 3D‐QSAR analysis of a series of novel purine derivatives synthesized was performed based on self‐organized molecular field analysis (SOMFA). Significant correlation coefficients (SOMFA, r2 = 0.821, rcv2 = 0.807, F value = 283.500, SEE = 0.229) were obtained, and the model prediction ability was validated using the test set. The results suggest that rational modification of the substituent groups can provide a basis for the development of more effective drug molecules.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) studied Cardiovascular disease (platelet aggregation). Novel purine derivatives was evaluated on Antiplatelet aggregation activity and 3D-QSAR analysis (SOMFA) (r2 = 0.821). 3D-QSAR analysis of novel purine derivatives yielded significant correlation coefficients (r2 = 0.821, rcv2 = 0.807), suggesting rational substituent modification can guide antithrombotic drug development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: